^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR34A (MicroRNA 34a-5p)

    i
    Other names: MIR34A, mir-34, MIRN34A, mir-34a, miRNA34A
    11d
    Gastric Cancer Epithelial-Mesenchymal Transition-The Role of Micro-RNA. (PubMed, Cancers (Basel))
    Several EMT-related miRNAs show consistent associations with invasion, metastasis, peritoneal dissemination, prognosis, and chemoresistance, and many are detectable in circulation. Overall, EMT-related miRNAs orchestrate gastric cancer cell plasticity and tumor-microenvironment crosstalk and represent promising biomarker and therapeutic candidates that warrant validation in prospective, subtype-stratified, and translational studies.
    Review • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • TGFB1 (Transforming Growth Factor Beta 1) • MIR192 (MicroRNA 192) • MIR27A (MicroRNA 27a) • MIR17 (MicroRNA 17) • MIR23A (MicroRNA 23a) • MIR375 (MicroRNA 375) • MIR506 (MicroRNA 506) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • MIR106B (MicroRNA 106b) • MIR130A (MicroRNA 130a) • MIR148A (MicroRNA 148a) • MIR150 (MicroRNA 150) • MIR181A1 (MicroRNA 181a-1) • MIR200 (MicroRNA 200) • MIR204 (MicroRNA 204) • MIR218 (MicroRNA 218) • MIR26A1 (MicroRNA 26a-1) • MIR30A (MicroRNA 30a)
    12d
    Investigation of the impact of image-guided radiotherapy selection on image registration results and non-coding RNAs for cervical cancer patients. (PubMed, Noncoding RNA Res)
    The results indicate that choosing bone and tumor landmarks as optimal registration points can improve the accuracy and efficacy of IGRT, leading to better treatment outcomes and reduced side effects. These findings offer scientific evidence and practical guidance for the utilization of IGRT in cervical cancer treatment, providing valuable technical support for future clinical practice.
    Journal
    |
    MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p)
    20d
    Cytokine MicroRNA regulatory networks in colorectal cancer: Contemporary research insights and mechanistic analysis. (PubMed, Cytokine Growth Factor Rev)
    Since the administration of targeted treatments can result in an immune-related adverse effect, growing interest has focused on exosomes as alternative carriers for miRNA-based therapeutics. Overall, applications of miRNAs have the potential to improve CRC outcomes.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR143 (MicroRNA 143) • MIR145 (MicroRNA 145)
    21d
    Circulating miRNAs combined with AFP improve diagnostic accuracy for HBV-associated hepatocellular carcinoma. (PubMed, Biochem Biophys Rep)
    When AFP was integrated, diagnostic performance improved markedly across all comparisons: AUC = 0.97 (HCC vs. CHB), 0.84 (HCC vs. LC), and 0.91 (HCC vs. non-HCC). Combining circulating miR-21-5p, miR-34a-5p, and miR-30d-3p with AFP significantly enhances diagnostic accuracy for HBV-related HCC, supporting their utility as complementary non-invasive biomarkers for early screening.
    Journal
    |
    AFP (Alpha-fetoprotein) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR30D (MicroRNA 30d)
    24d
    Investigation of the Correlation Between Selected miRNAs, Proinflammatory Cytokines, and Serum Trace Elements in Bladder Cancer Development and Progression. (PubMed, Curr Issues Mol Biol)
    A significant positive correlation was detected between miRNA-34a and IL-6 and TGF-β (r = 0.294*, p = 0.010; r = 0.447**, p < 0.001). By evaluating these important biomarkers together, it might be possible to implement clinical applications for bladder cancer treatment and develop individual therapeutic strategies.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • TGFB1 (Transforming Growth Factor Beta 1)
    26d
    Ultrasensitive MicroRNA Detection Combining Reduced Graphene Oxide Electrolyte-Gated Transistors and Machine Learning. (PubMed, Small)
    ML enables multidimensional analysis of EGT transfer curves and extraction of physically meaningful features from high-dimensional data. This approach advances point-of-care technologies for highly sensitive and selective miRNA detection, with strong potential for portable molecular diagnostics.
    Journal
    |
    MIR34A (MicroRNA 34a-5p) • MIR34B (MicroRNA 34b)
    1m
    The Role of microRNAs as Potential Biomarkers in Diffuse Large B-Cell Lymphoma. (PubMed, Noncoding RNA)
    While novel therapies such as rituximab and polatuzumab vedotin have led to improved outcomes, approximately 35% of patients eventually develop relapsed or refractory disease. Among these, miR-155 and miR-21 are particularly well studied, playing central roles in both tumor progression and remodeling of the tumor microenvironment. This review summarizes current evidence on the biological and clinical relevance of miRNAs in DLBCL, emphasizing their diagnostic and prognostic potential.
    Review • Journal
    |
    MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • MIR34A (MicroRNA 34a-5p) • MIR17 (MicroRNA 17) • MIR181A1 (MicroRNA 181a-1) • MIR124-3 (MicroRNA 124-3)
    |
    Rituxan (rituximab) • Polivy (polatuzumab vedotin-piiq)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    1m
    MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review. (PubMed, Diagnostics (Basel))
    Overall, current evidence supports miRNAs as promising diagnostic, prognostic, and predictive biomarkers in cutaneous oncology. Standardized methodologies and large-scale validation remain essential for their integration into routine clinical practice.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • MIR34A (MicroRNA 34a-5p) • MIR182 (MicroRNA 182) • MIR18A (MicroRNA 18a) • MIR31 (MicroRNA 31) • MIR375 (MicroRNA 375) • MIR128 (MicroRNA 128) • MIR145 (MicroRNA 145) • MIR181A1 (MicroRNA 181a-1) • MIR203A (MicroRNA 203a) • MIR205 (MicroRNA 205) • MIR383 (MicroRNA 383)
    |
    BRAF mutation
    2ms
    Mechanic Exploration of Yin Jia Tablet Against Chronic Salpingitis via the miR-34a-5p-Mediated ceRNA Network. (PubMed, J Ethnopharmacol)
    YJT exerts multitarget protective effects against CS by regulating the miR-34a-5p-related ceRNA network, which in turn suppresses inflammatory responses and preserves the normal function of the oviduct. These findings provide molecular evidence for the pharmacological basis of YJT in the treatment of CS and further support its potential as a promising therapeutic agent for this condition.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR34A (MicroRNA 34a-5p) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta)
    2ms
    [Retracted] MicroRNA-34a suppresses breast cancer cell proliferation and invasion by targeting Notch1. (PubMed, Exp Ther Med)
    &lsqb;This retracts the article DOI: 10.3892/etm.2018.6744.].
    Journal
    |
    NOTCH1 (Notch 1) • MIR34A (MicroRNA 34a-5p)
    2ms
    INTEGRATED EXPRESSION PROFILE OF THE MMP-TIMP-MIRNA AXIS IN BREAST CANCER CELL LINES OF DIFFERENT MOLECULAR SUBTYPES. (PubMed, Exp Oncol)
    The study demonstrates that the MMP-TIMP-miRNA axis exhibits subtype-specific expression patterns in the BC cell lines. The observed heterogeneity highlights the importance of post-transcriptional regulation and suggests that integrated profiling of MMPs, TIMPs, and regulatory miRNAs may provide novel insights into the invasive potential of BC and identify candidate biomarkers for clinical validation.
    Preclinical • Journal
    |
    MIR155 (MicroRNA 155) • MIR200B (MicroRNA 200b) • MMP2 (Matrix metallopeptidase 2) • MIR34A (MicroRNA 34a-5p) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • MIR100 (MicroRNA 100) • MMP9 (Matrix metallopeptidase 9) • MIR132 (MicroRNA 132) • MMP1 (Matrix metallopeptidase 1) • MIR145 (MicroRNA 145) • MMP8 (Matrix Metallopeptidase 8) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)